Treatment Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

Posted by on Jul 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the...

Read More

Comparing second-line therapy options combined with metformin for patients with type 2 diabetes.

Comparing second-line therapy options combined with metformin for patients with type 2 diabetes.

Posted by on Jul 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study explored the effects of different second-line therapies combined with metformin (Glucophage) in patients with type 2 diabetes (T2D). The data showed that metformin combinations with a sulfonylurea (SU) had the lowest weight loss, the smallest effect of lowering blood glucose, and an overall, reduced health...

Read More

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL).  This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...

Read More

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Health-related quality of life in patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva).  This study concluded that this treatment is effective and does not impair the quality of life in these...

Read More

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Posted by on Jul 25, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients. Some background Colorectal cancer (CRC) is one of...

Read More

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Posted by on Jul 25, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) versus lapatinib (Tykerb) plus capecitabine in patients with human epidermal growth factor (HER2)-positive breast cancer (BC) spread (metastases) to the central nervous system (CNS; brain and spinal cord). The data showed that the...

Read More

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients.  Some background BC is...

Read More

Reviewing effectiveness and safety of greenlight photo-selective vaporization of the prostate in patients with benign prostatic hyperplasia.

Reviewing effectiveness and safety of greenlight photo-selective vaporization of the prostate in patients with benign prostatic hyperplasia.

Posted by on Jul 21, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study characterized the safety and effectiveness of greenlight photo-selective vaporization of the prostate (GL-PVP) in the treatment of benign prostatic hyperplasia (BPH). The data showed that under real-world conditions, GL-PVP provides a safe, effective, and durable BPH treatment option. Some background Lower urinary tract...

Read More

Is filgotinib with background methotrexate an option for patients with rheumatoid arthritis?

Is filgotinib with background methotrexate an option for patients with rheumatoid arthritis?

Posted by on Jul 21, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared the benefit of two doses of filgotinib (Jyseleca) with adalimumab (Humira) and placebo, in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX; Otrexup). The data showed that filgotinib reduced RA signs, improved physical activity, prevented structural joint damage progression, and was...

Read More

Comparing surgery alone and surgery plus chemotherapy for limited-stage small-cell lung cancer

Comparing surgery alone and surgery plus chemotherapy for limited-stage small-cell lung cancer

Posted by on Jul 21, 2021 in Lung cancer | 0 comments

In a nutshell This analysis was carried out to assess the outcomes of patients who underwent surgery only or surgery and chemotherapy (CT) for limited-stage small-cell lung cancer (LS-SCLC). The authors found that surgery plus CT resulted in better outcomes compared to surgery alone.  Some background SCLC is an aggressive type of...

Read More

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

Posted by on Jul 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients. Some background Localized prostate cancer...

Read More